Understanding why some bladder cancer patients respond or resist ADC-immunotherapy combos
Official title: Project 1: Elucidating Mechanisms of Sensitivity and Resistance to Combination Antibody-Drug Conjugate Therapy and Immunotherapy in Urothelial Cancer
Funded at Sloan-Kettering Inst Can Research · NIH-11335849 · Data updated 2026-11-12
A research project looks at why some bladder cancer patients benefit from antibody-drug conjugate therapy combined with immunotherapy and why others don’t.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 18, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $499,767 |
| NIH project number | 1P50CA310825-01 |
| Project ID | NIH-11335849 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with metastatic or regionally advanced urothelial (bladder) cancer who are treated with EV+P or are being considered for EV+P as part of standard care or presurgical trials.
✕Less likely to help
Patients not receiving EV+P or not participating in presurgical trials may not benefit from the findings.
What this research studies
This project focuses on bladder cancer patients treated with antibody-drug conjugates such as enfortumab vedotin plus pembrolizumab. It will analyze tumor tissue and blood samples before and after treatment to uncover clues about response and resistance. By linking immune responses and tumor characteristics, the study aims to identify markers and mechanisms that could guide better, personalized treatment decisions. The work uses patient-derived samples from standard care and from an investigator-initiated trial to explore how immune activation relates to durable responses.
Why it matters
Potential benefit: If successful, patients could receive more effective, personalized therapies with fewer ineffective treatments.
How similar studies have gone: Previous studies show promising responses with EV+P, but resistance remains common, so this work builds on partially successful approaches with deeper mechanistic insight.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Rosenberg, Jonathan Eric — Sloan-Kettering Inst Can Research
- Study coordinator: Rosenberg, Jonathan Eric
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.